May 2 |
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
|
Apr 9 |
/C O R R E C T I O N -- enGene Inc./
|
Mar 12 |
enGene Holdings GAAP EPS of -$0.46
|
Mar 11 |
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
|
Mar 5 |
enGene To Present at the Leerink Partners Global Biopharma Conference
|
Feb 15 |
Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
|
Feb 15 |
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
|
Feb 14 |
Dow Edges Higher; QuidelOrtho Shares Plummet
|
Feb 14 |
enGene stock up on private placement announcement, CEO resigns
|
Feb 14 |
enGene Announces Oversubscribed $200 Million Private Placement Financing
|